High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: Pathologic response and outcome

Bone Marrow Transplantation

Volumn 21, Issue 3, 1998, Pages 249-254

  Viens, P ^a   Penault Llorca, F ^a   Jacquemier, J ^a   Gravis, G ^a   Cowen, D ^a   Bertucci, F ^a   Houvenaeghel, G ^a   Biaise, D ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

High dose chemotherapy; Inflammatory breast cancer; Pathologic response; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MELPHALAN; MITOXANTRONE;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRIORITY JOURNAL; RELAPSE;

EID: 0031962335     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701074     Document Type: Article

References (35)

1. Denoix P (ed). The Institut's contribution to the definition of factors guiding the choice of treatment: phase I development: treatment of malignant breast tumours. In: Recent Results in Cancer Research. Springer-Verlag: Berlin, 1970, p 3-11.
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10: 1014-1024.
3. Barker J, Montague E, Peters L. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 1980; 45: 625-629.
4. Rouëssé J, Friedman S, Sarrazin D et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4: 1765-1771.
5. Koh EH, Buzdar AU, Ames FC et al. Inflammatory carcinoma of the breast: results of a combined-modality approach - MD Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990; 27: 94-100.
6. Pisansky TM, Schaid DJ, Loprinzi CL et al. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol 1992; 15: 376-387.
7. Bauer RL, Busch E, Levine E, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol 1995; 2: 288-294.
8. Feldman LD, Hortobagyi GN, Buzdar AU et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-2581.
9. Maloisel F, Dufour P, Bergerat JP et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990; 65: 851-855.
10. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-304.
11. Frei EI, Canellos P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-594.
12. Skipper HE. Dose intensity versus total dose of chemotherapy: an experimental basis. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. JB Lippincott: Philadelphia, 1990, pp 43-64.
13. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
14. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. New Engl J Med 1981; 304: 10-15.
15. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
16. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
17. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
18. Faucher C, Le Corroller AG, Chabannon C et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematol 1996; 5: 663-670.
19. Viens P, Stoppa AM, Blaise D et al. Combination of alkylating agent and mitoxantrone with autologous bone marrow transplantation for poor prognosis breast cancer. A phase I study. Bone Marrow Transplant 1990; 5 (Suppl. 2): 22 (Abstr. 40).
20. Jacquemier J, Moles JP, Penault-Llorca F. et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994; 69: 846-852.
21. Chevallier B, Chollet P, Merrouche Y et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-1571.
22. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1957; 53: 457-471.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-191.
24. Israël L, Breau JL, Morere JF. Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. Cancer 1986; 57: 24-28.
25. Noguchi S, Miyauchi K, Nishizawa Y et al. Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients. Cancer 1988; 61: 1483-1491.
26. Armstrong DK, Fetting JH, Davidson NE et al. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993; 28: 277-284.
27. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FECHD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
28. Colozza M, Gori S, Mosconi AM et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol 1996; 19: 10-17.
29. Antman K, Gale RP. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570-574.
30. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 1994; 330: 1260-1266.
31. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 10: 2483-2489.
32. Palangie T, Mosseri V, Mihura J et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994; 30A: 921-927.
33. Shea TC, Mason JR, Storniolo AM et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10: 464-473.
34. Pettengell R, Woll PJ, Thatcher N et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-156.
35. Viens P, Gravis G, Genre D et al. High dose sequential chemotherapy with stem cell support for non metastatic breast cancer. Bone Marrow Transplant 1997; 20: 199-203.